• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

FINASTERIDE Drug Record

  • Summary
  • Interactions
  • Claims
  • FINASTERIDE chembl:CHEMBL710 ApprovedAntineoplastic

    Alternate Names:

    PROPECIA
    PROSTIDE
    AINDEEM
    FINASTERIDE
    MK-906
    PROSCAR
    (5ALPHA,17BETA)-(1,1-DIMETHYLETHYL)-3-OXO-4-AZAANDROST-1-ENE-17-CARBOXAMIDE
    FINASTERIDA
    FINASTERIDUM
    PROPECIA®
    PROSCAR®
    MK906
    MK 906
    pubchem.compound:57363
    drugbank:01216
    rxcui:25025
    chembl:CHEMBL710
    chemidplus:98319-26-7

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antineoplastic agent
    Drug Class anti-baldness agents
    Drug Class antihyperplasia agents
    Year of Approval 1992
    (3 More Sources)

    Publications:

    Bowman et al., 2003, Effects of in utero exposure to finasteride on androgen-dependent reproductive development in the male rat., Toxicol. Sci.
    Smith et al., 2009, Finasteride in the treatment of patients with benign prostatic hyperplasia: a review., Ther Clin Risk Manag
    Goldenberg et al., 2009, The role of 5-alpha reductase inhibitors in prostate pathophysiology: Is there an additional advantage to inhibition of type 1 isoenzyme?, Can Urol Assoc J
    Ha et al., 2003, Analysis of genetic polymorphisms of steroid 5alpha-reductase type 1 and 2 genes in Korean men with androgenetic alopecia., J. Dermatol. Sci.
    Suzuki et al., 2010, Saturable binding of finasteride to steroid 5alpha-reductase as determinant of nonlinear pharmacokinetics., Drug Metab. Pharmacokinet.
    Xu et al., 2006, Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers., Clin. Cancer Res.
    Joseph et al., 2005, Hidradenitis suppurativa treated with finasteride., J Dermatolog Treat
    Sáez et al., 1999, Expression of basic fibroblast growth factor and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride., Prostate
    Drury et al., 2009, Inhibition of human steroid 5beta-reductase (AKR1D1) by finasteride and structure of the enzyme-inhibitor complex., J. Biol. Chem.
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Sawaya et al., Androgen responsive genes as they affect hair growth., Eur J Dermatol
    Levy et al., 1995, Cloning, expression and functional characterization of type 1 and type 2 steroid 5 alpha-reductases from Cynomolgus monkey: comparisons with human and rat isoenzymes., J. Steroid Biochem. Mol. Biol.
    Tian et al., 1994, 17 beta-(N-tert-butylcarbamoyl)-4-aza-5 alpha-androstan-1-en-3-one is an active site-directed slow time-dependent inhibitor of human steroid 5 alpha-reductase 1., Biochemistry
    Thigpen et al., 1992, Four-amino acid segment in steroid 5 alpha-reductase 1 confers sensitivity to finasteride, a competitive inhibitor., J. Biol. Chem.
    Rittmaster et al., 1995, Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5 alpha-reductase inhibitor finasteride., Endocrinology
  • FINASTERIDE   SRD5A2

    Interaction Score: 23.78

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Steroid 5-alpha-reductase 2 inhibitor
    Trial Name YM-152, finasteride

    PMIDs:
    12773767 19707263 19543428 12670724 20460827 16818707 16019620


    Sources:
    TdgClinicalTrial ChemblInteractions TTD

  • FINASTERIDE   AKR1D1

    Interaction Score: 9.51

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name YM-152, finasteride
    Novel drug target Established target

    PMIDs:
    19515843


    Sources:
    TdgClinicalTrial

  • FINASTERIDE   SRD5A1

    Interaction Score: 6.66

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name YM-152, finasteride
    Novel drug target Established target

    PMIDs:
    7734398 19707263 8117686 1314830 20460827


    Sources:
    TdgClinicalTrial TEND

  • FINASTERIDE   CFLAR

    Interaction Score: 1.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11399535


    Sources:
    NCI

  • FINASTERIDE   TGM2

    Interaction Score: 0.45

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7835306


    Sources:
    NCI

  • FINASTERIDE   FGFR1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10386468


    Sources:
    NCI

  • FINASTERIDE   CYP2C9

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • FINASTERIDE   CYP2C19

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • FINASTERIDE   CYP1A2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • FINASTERIDE   CYP2D6

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • FINASTERIDE   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • FINASTERIDE   NFE2L2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • FINASTERIDE   AR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: FINASTERIDE

    • Version: 01-August-2011

    Alternate Names:
    FINASTERIDE Primary Drug Name

    Drug Info:
    Year of Approval 1992
    Drug Class antihyperplasia agents
    Drug Class anti-baldness agents

    Publications:

  • TdgClinicalTrial: FINASTERIDE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: FINASTERIDE

    • Version: 14-September-2017

    Alternate Names:
    C1099 NCI drug code

    Drug Info:

    Publications:
    Sawaya et al., Androgen responsive genes as they affect hair growth., Eur J Dermatol
    Rittmaster et al., 1995, Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5 alpha-reductase inhibitor finasteride., Endocrinology
    Sáez et al., 1999, Expression of basic fibroblast growth factor and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride., Prostate

  • DTC: FINASTERIDE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL710 ChEMBL Drug ID

    Drug Info:

    Publications:
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol

  • TTD: Finasteride

    • Version: 2020.06.01

    Alternate Names:
    D08IWD TTD Drug ID

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL710

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL710

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21